Advanced Drug Delivery Systems: New Developments, New Technologies
October 13, 2009
Wellesley, Mass. – According to a new technical market research report, Advanced Drug Delivery Systems: New Developments, New Technologies (PHM006G) from BCC Research (www.bccresearch.com), the global market for advanced drug delivery systems amounted to $134.3 billion in 2008, and is projected to increase to $139 billion in 2009. The estimate for 2014 is $196.4 billion, for a compound annual growth rate (CAGR) of 7.2% in the 5-year period.
Over the last decade, the drug-delivery industry has evolved as a key aspect in the development of value-added pharmaceutical products. Pharmaceutical companies have increasingly turned to drug-delivery technologies to enhance drug efficacy, expand the life cycle of their products, and to boost their revenues.
In this very complex market, many technologies are combined together to produce a better delivery system, thus creating niche markets with very specialized applications. The use of liposomes, polymers, etc., in the sustained-release, oral/injectable drug-delivery market is a good example. Prodrugs, PEGylation, nanoparticles, and liposomes are among the significant new markets evaluated in this BCC study.
SUMMARY FIGURE
GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, 2007-2014
($ BILLIONS)
To Contact us, click here 
Source: BCC Research
Monoclonal antibodies made up the largest market among all the drug delivery products, with $35.9 billion in sales in 2008. The sustained-release, oral-dosage products stood at second position, with sales of $35.1 billion in 2008. These markets are expected to grow further with the introduction of novel agents like tazarotene dapsone, Mirena for contraception, and rivastigmine transdermal patch for Alzheimer’s disease and multiple sclerosis. Certain other products are in the pipeline and have the potential to significantly improve the efficacy of the drug delivery market.
The report finds that the drug delivery market is now changing drastically due to the introduction of new techniques and routes of delivery. R&D spending, along with increasing competition, patent expiries, new technologies, an international marketplace, and a changing customer base, is creating a new kind of market for drug-delivery systems. Advanced Drug Delivery Systems: New Developments, New Technologies looks at almost all the systems affected by these factors.
Advanced Drug Delivery Systems: New Developments, New Technologies( PHM006G )
Publish Date: Aug 2009
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
Advanced Drug Delivery Systems: New Developments, New Technologies
Customize This Report More in Pharmaceuticals
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum
- Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030
- AI in Clinical Trials Poised for Rapid Growth with a 22.6% CAGR Forecast
Reports from Pharmaceuticals
Recent News
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand